X. Long Zheng/LinkedIn
Sep 22, 2026, 07:18
X. Long Zheng: From ADAMTS13 to New TTP Treatment
X. Long Zheng, Professor and Chair of Pathology and Laboratory Medicine at The University of Kansas, shared a post on LinkedIn:
“I had a great time as a visiting professor at Montefiore Medical Center to meet with pathology residents/faculty and discuss the 100-year research and development in TTP (thrombotic thrombocytopenic purpura).
Progress has been particularly accelerated since the molecular identification and cloning of ADAMTS13, a key enzyme that is deficient in patients with TTP.
ADAMTS13 is now a FDA-approved drug for treatment of congenital TTP.”
Stay updated with Hemostasis Today.
-
Sep 22, 2026, 07:11Platelet Dependent Protection Against Bacterial Pneumonia – JTH
-
Sep 22, 2026, 07:10Sumita Pandey: Apheresis Beyond Automation
-
Sep 22, 2026, 07:04Wafik El-Deiry: Type 1 interferon Alters Clonal Competition in Human Blood Development
-
Sep 22, 2026, 06:53Tania L.: Women in Hematology Take the Stage in Austin
-
Sep 22, 2026, 06:35Mahmoud Hanafy: Hayat National Hospitals Achieves AABB Accreditation
-
Sep 22, 2026, 06:01Nikola Pantic: New ASH ITP Guidelines Transform First-Line Treatment
-
Sep 22, 2026, 04:43Michael Cahillane: Highlights From BBTS2026 in Glasgow
-
Sep 22, 2026, 04:15Wolfgang Miesbach: First AAV Gene Therapy Data in Adolescents With Haemophilia B
-
Sep 22, 2026, 04:03Emmanuel J Favaloro: 100 Years of VWD – A Special Virtual Issue